A preparation of herbal medicine Salvia miltiorrhiza reduces expression of intercellular adhesion molecule-1 and development of atherosclerosis in apolipoprotein E-deficient mice

Journal of Cardiovascular Pharmacology
Shanhong LingPaul A Komesaroff

Abstract

Cardiotonic pill (CP) is a pharmaceutical preparation of the herbal medicine Salvia miltiorrhiza. In vitro studies demonstrate that CP inhibits vascular endothelial expression of adhesion molecules and smooth-muscle proliferation, implying the possibility of antiatherosclerotic effects. This study employs an in vivo animal model to examine the potential therapeutic efficacy of CP on atherosclerotic development. Male apolipoprotein E-deficient (ApoE-/-) mice fed with an atherogenic (high fat) diet were administered with CP (90-120 mg/kg per day) via drinking water for 8 weeks. Hypercholesterolemia developed in the mice, with 22-fold increases in plasma levels of total cholesterol, 29-fold of LDL, and 7-fold of HDL. CP therapy did not significantly alter the lipid levels. Expression of intercellular adhesion molecule 1 significantly increased in circulating leukocytes and was abolished by CP therapy. Atherosclerosis significantly developed in the aorta and was attenuated by CP therapy, with an approximately 30% reduction in whole atherosclerotic lesions and an approximately 50% reduction in fibrous plaques in the artery. Thus, herbal medicine CP partly protects ApoE-/- mice from high-fat diet-induced atherogenesis. The protection...Continue Reading

References

Sep 1, 1994·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·J H QiaoA J Lusis
Jan 14, 1999·The New England Journal of Medicine·R Ross
Feb 8, 2000·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·G Y ZhouW J Xin
Sep 19, 2000·Free Radical Research·X L NiuH Nakazawa
Oct 27, 2001·Acta Physiologica Scandinavica·Y Huo, K Ley
Dec 25, 2002·Japanese Journal of Pharmacology·De Cheng RenJun Tian Zhang
Nov 13, 2003·Atherosclerosis·Stefan BlankenbergLaurence Tiret
May 18, 2004·Journal of Neuroimmunology·Mary Ann T GimenezJohn H Russell
Dec 29, 2004·Journal of Pharmaceutical and Biomedical Analysis·Jin-lan ZhangDe-an Guo
Jul 20, 2005·Clinical and Experimental Pharmacology & Physiology·Shanhong LingPaul A Komesaroff
Oct 7, 2005·International Journal of Cardiology·Daniel P SievekingDavid S Celermajer
Nov 18, 2005·Journal of Clinical Pharmacology·Limin ZhouMoses Sing Sum Chow

❮ Previous
Next ❯

Citations

Dec 26, 2012·Biochemical and Biophysical Research Communications·Seung-Lark HwangHyeun Wook Chang
Jul 22, 2011·Atherosclerosis·Si GaoSuowen Xu
Oct 29, 2008·Evidence-based Complementary and Alternative Medicine : ECAM·Kylie A O'BrienPaul A Komesaroff
Apr 27, 2018·Acta Pharmacologica Sinica·Zhuo-Ming LiPei-Qing Liu
Mar 1, 2018·Pharmaceutical Biology·Emily Guzman, Jeanmaire Molina
Aug 24, 2012·Menopause : the Journal of the North American Menopause Society·Chun-mei LiShun-wan Chan

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Cell Adhesion Molecules in AS

Cell adhesion molecules expressed on the vascular endothelium and circulating leukocytes in response to inflammatory stimuli are implicated in atherosclerosis. Here is the latest research.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.